Format

Send to

Choose Destination
Neurobiol Dis. 2019 Oct;130:104503. doi: 10.1016/j.nbd.2019.104503. Epub 2019 Jun 13.

Modeling Alzheimer's disease with human iPS cells: advancements, lessons, and applications.

Author information

1
Department of Molecular and Cellular Physiology, Stanford University Medical School, Stanford, CA 94305, United States of America.
2
Department of Molecular and Cellular Physiology, Stanford University Medical School, Stanford, CA 94305, United States of America; Institute for Stem Cell Biology and Regenerative Medicine and Department of Pathology, Stanford University Medical School, Stanford, CA 94305, United States of America.
3
Institute for Stem Cell Biology and Regenerative Medicine and Department of Pathology, Stanford University Medical School, Stanford, CA 94305, United States of America.
4
Department of Molecular and Cellular Physiology, Stanford University Medical School, Stanford, CA 94305, United States of America. Electronic address: alvinhuang@stanford.edu.

Abstract

One in three people will develop Alzheimer's disease (AD) or another dementia and, despite intense research efforts, treatment options remain inadequate. Understanding the mechanisms of AD pathogenesis remains our principal hurdle to developing effective therapeutics to tackle this looming medical crisis. In light of recent discoveries from whole-genome sequencing and technical advances in humanized models, studying disease risk genes with induced human neural cells presents unprecedented advantages. Here, we first review the current knowledge of the proposed mechanisms underlying AD and focus on modern genetic insights to inform future studies. To highlight the utility of human pluripotent stem cell-based innovations, we then present an update on efforts in recapitulating the pathophysiology by induced neuronal, non-neuronal and a collection of brain cell types, departing from the neuron-centric convention. Lastly, we examine the translational potentials of such approaches, and provide our perspectives on the promise they offer to deepen our understanding of AD pathogenesis and to accelerate the development of intervention strategies for patients and risk carriers.

KEYWORDS:

Alzheimer’s disease (AD); Amyloid-β (Aβ); Apolipoprotein E (apoE); Astrocytes; Blood-brain barrier (BBB); Genetic risk; Induced pluripotent stem cell (iPSC); Microglia; Oligodendrocytes; Tau

PMID:
31202913
PMCID:
PMC6689423
[Available on 2020-10-01]
DOI:
10.1016/j.nbd.2019.104503

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center